

For immediate release

## Perrigo Company plc Rule 2.10 Announcement

DUBLIN, Ireland — April 9, 2015 — In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, Perrigo Company plc (NYSE: PRGO; TASE) ("Perrigo" or "The Company") confirms that as of 8 April 2015 its issued share capital is comprised of 146,221,031 ordinary shares of €0.001 each (the **Ordinary Shares**). The Ordinary Shares are admitted to trading on the New York Stock Exchange under the ticker symbol PRGO. The International Securities Identification Number for these securities is IE00BGH1M568.

Perrigo confirms that, as of 8 April 2015, there were 907,748 vested and unvested options to purchase Ordinary Shares, 229,160 performance stock units and 273,371 restricted stock units granted by Perrigo.

## **About Perrigo**

Perrigo Company plc, a top five global over-the-counter (OTC) consumer goods and pharmaceutical company, offers consumers and customers high quality products at affordable prices. From its beginnings in 1887 as a packager of generic home remedies, Perrigo, headquartered in Ireland, has grown to become the world's largest manufacturer of OTC products and supplier of infant formulas for the store brand market. The Company is also a leading provider of branded OTC products, generic extended topical prescription products and receives royalties from Multiple Sclerosis drug Tysabri®. Perrigo provides "Quality Affordable Healthcare Products®" across a wide variety of product categories and geographies primarily in North America, Europe, and Australia, as well as other key markets including Israel and China. Visit Perrigo online at (<a href="http://www.perrigo.com">http://www.perrigo.com</a>).

The Directors of Perrigo accept responsibility for the information contained in this announcement. To the best of their knowledge and belief (having taken all reasonable care to ensure such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.

A person interested in 1% or more of any class of relevant securities of Perrigo or Mylan N.V. may have disclosure obligations under Rule 8.3 of the Irish Takeover Rules.

A copy of this announcement will be available on Perrigo's website at <a href="www.perrigo.com">www.perrigo.com</a>.

## **Enquiries**

Arthur J. Shannon, Vice President, Investor Relations and Global Communications (269) 686-1709

E-mail: ajshannon@perrigo.com

Bradley Joseph, Director, Investor Relations and Global Communications

(269) 686-3373 E-mail: bradley.joseph@perrigo.com

2 M-24331032-2